SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Abrysvo

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since mid-2023.
Why 4/10
Abrysvo is already approved and commercialized with no pending regulatory decision (PDUFA or pivotal readout) in the next 12 months. It is a meaningful product but represents a small fraction of Pfizer's $62-64 billion annual revenue. The next catalysts are quarterly sales reports, which are not binary events. Per the rubric, an approved drug with no upcoming binary scores 3-5, and 4 reflects its moderate commercial importance within a diversified giant.
Actionable Insight NEUTRAL

Abrysvo has no upcoming PDUFA dates or pivotal readouts; it is an approved, commercial product. Watch Pfizer's quarterly earnings reports for Abrysvo sales trends, particularly during the fall RSV season (September-January). The key competitive dynamic to monitor is whether Abrysvo can gain market share from GSK's Arexvy following its broader adult label (18-59 at-risk) and whether the GBS warning materially impacts uptake.

Price Chart

Loading chart...

Executive Summary

Abrysvo is Pfizer's FDA-approved respiratory syncytial virus (RSV) vaccine, launched in mid-2023. It holds a unique position as the only RSV vaccine approved for pregnant women to protect newborns and the only one approved for adults as young as 18 (at-risk). However, it faces stiff competition from GSK's Arexvy, which dominates the market, and Moderna's mRESVIA. Sales have declined from $890 million in its first year to $755 million in 2024, and a GBS warning was added to the label in January 2025. For Pfizer, a $62-64 billion revenue company, Abrysvo is a meaningful but not dominant product, and no upcoming binary regulatory catalysts are scheduled.

How It Works

Abrysvo is a vaccine that trains the immune system to recognize and fight respiratory syncytial virus (RSV). It contains a purified version of a key RSV surface protein (the prefusion F protein) from two major RSV subtypes (A and B). When injected, the body produces antibodies against this protein, blocking the virus from entering cells. In pregnant women, these antibodies cross the placenta and protect the newborn for the first six months of life.

Trial Status

Abrysvo was approved by the FDA in May 2023 for adults 60 and older, in August 2023 for pregnant individuals to protect infants, and in October 2024 for adults aged 18-59 at increased risk of severe RSV. The pivotal Phase 3 MATISSE trial (NCT04424316) enrolled over 7,000 pregnant individuals and demonstrated efficacy against RSV-associated lower respiratory tract disease in infants. Post-marketing observational studies are ongoing, including a real-world effectiveness study with the University of Pittsburgh.

The Two-Sided Case

▲ Bull Case4
Abrysvo is the only RSV vaccine approved for pregnant individuals to protect infants, giving it a unique market position that competitors GSK (Arexvy) and Moderna (mRESVIA) cannot match.
Abrysvo has the broadest adult label of any RSV vaccine, covering adults 18-59 at increased risk, whereas GSK's Arexvy and Moderna's mRESVIA are only approved for ages 50+.
Pfizer's Q3 2026 earnings (Nov 3, 2026) beat estimates, and the company raised full-year 2026 guidance, with launched/acquired products (including Abrysvo) growing 32% operationally year-over-year.
The global RSV vaccine market is projected to grow from $1.1 billion in 2026 to $3.4 billion by 2034 (CAGR 15.2%), providing a long tailwind for Abrysvo as vaccination rates increase.
▼ Bear Case5
Abrysvo sales declined from $890 million in 2023 (first year) to $755 million in 2024, and Q3 2025 and Q3 2026 both showed year-over-year sales declines amid a tough US vaccine market and narrowed CDC recommendations.
GSK's Arexvy dominates the RSV vaccine market with roughly two-thirds market share and $1.5 billion+ in annual sales, significantly outselling Abrysvo.
In January 2025, the FDA required a Guillain-Barre syndrome (GBS) warning on Abrysvo's label, which may dampen consumer and physician uptake.
The CDC narrowed RSV vaccine recommendations in 2024 to a routine age-based recommendation only for adults 75+ and a risk-based recommendation for ages 60-74, shrinking the addressable market.
Abrysvo is a small part of Pfizer's overall business (Pfizer's 2025 revenue was $62.6 billion), so even strong Abrysvo performance has limited impact on PFE's stock price.

Upcoming Catalysts

  • No upcoming PDUFA dates or pivotal readouts identified for Abrysvo; it is an approved, marketed product. Future catalysts are limited to quarterly sales reports and potential label expansions (e.g., pediatric use, which is under investigation per EMA requirements).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 fda.gov2 fda.gov3 pfizer.com4 fda.gov5 reuters.com6 fiercepharma.com7 cnbc.com8 fortunebusinessinsights.com9 cdc.gov10 guidechem.com11 pharmaphorum.com12 fiercepharma.com